Nexalin Technology, Inc. NXL
Institutional shares held
276,263
0
calls
0
puts
Total value of holdings
$221K
$0
calls
$0
puts
Market Cap
$4.88M
7,279,960
Shares Out.
Institutional ownership
3.79%
# of Institutions
14
We take great care to ensure that the data presented and summarized in this overview for Nexalin Technology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NXL
View all-
Morgan Stanley New York, NY59.8KShares$40,0690.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE55.5KShares$37,1590.81% of portfolio
-
Geode Capital Management, LLC Boston, MA44.1KShares$29,5210.0% of portfolio
-
Atria Wealth Solutions, Inc. New York, NY38.4KShares$25,7360.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA31.8KShares$21,2920.0% of portfolio
-
State Street Corp Boston, MA16.8KShares$11,2560.0% of portfolio
-
Squarepoint Ops LLC New York, NY12.6KShares$8,4620.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY9.87KShares$6,6120.0% of portfolio
-
Ubs Group Ag4.04KShares$2,7040.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ3KShares$2,0100.0% of portfolio
Latest Institutional Activity in NXL
Top Purchases
Top Sells
About NXL
Insider Transactions at NXL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 23
2024
|
Marilyn Elson > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
700,000
+31.32%
|
-
|
|
Aug 13
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.67%
|
$0
$0.95 P/Share
|
|
Jun 28
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.68%
|
$1,000
$1.75 P/Share
|
|
Jun 18
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,619
+1.1%
|
$0
$0.71 P/Share
|
|
Jun 10
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+1.03%
|
$0
$0.64 P/Share
|
|
Sep 28
2022
|
Marilyn Elson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
9,500
+1.12%
|
$9,500
$1.12 P/Share
|
|
Sep 16
2022
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.74%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Mark White President/CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+0.86%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Rick Morad Director |
BUY
Open market or private purchase
|
Direct |
2,500
+2.26%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Alan Kazden Director |
BUY
Open market or private purchase
|
Indirect |
2,500
+2.73%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Marilyn Elson > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
36,000
+4.18%
|
$144,000
$4.15 P/Share
|
Last 12 Months Summary
Buy / Acquisition
707K
Shares
From
2
Insiders
| Grant, award, or other acquisition | 700K shares |
|---|---|
| Open market or private purchase | 6.62K shares |
Sell / Disposition
0
Shares
From
0
Insiders